Education
About Us
Working with TipRanks
Follow Us
Bavarian Nordic A/S (BVNRY)
OTHER OTC:BVNRY
Earnings Data
Report Date
May 09, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.07Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 05, 2025
|% Change Since: 0.91%
|Next Earnings Date:May 09, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance in 2024 with significant revenue growth, successful strategy execution, and new pipeline developments. However, there are challenges with certain product revenues and gross margin targets, as well as uncertainties related to U.S. regulatory processes. Overall, the positive aspects outweigh the challenges.Company Guidance
During the Bavarian Nordic 2024 Annual Report Conference call, the company provided strong financial guidance for 2025, projecting revenue between DKK5.7 billion to DKK6.7 billion and maintaining an EBITDA margin of 26% to 30%. The company's Travel Health vaccine franchise experienced a 22% growth, contributing to the overall 2024 revenue of just over DKK5.7 billion with a 28% EBITDA margin, equating to DKK1.6 billion. The 2024 fiscal year saw the successful completion of the tech transfer for rabies, with TBE expected to complete later in the year, and strong growth in public preparedness due to a health crisis involving mpox, securing contracts for over 3 million doses. For 2025, Bavarian Nordic has already secured DKK2.5 billion in public preparedness contracts, with the expectation of delivering DKK3 billion to DKK4 billion in that sector. The company also highlighted strategic advances, including new pipeline assets and the successful U.S. and EU approval of their Chikungunya vaccine, VIMKUNYA, projecting sales of DKK50 million to DKK100 million for this vaccine in 2025.Strong Revenue and EBITDA Margin
Bavarian Nordic reported a revenue of DKK5.7 billion for 2024 with a 28% EBITDA margin, marking the fifth consecutive year of profitable growth.
Travel Health Vaccine Franchise Growth
The Travel Health vaccine franchise grew by 22% compared to the previous year, driven by a 16% increase in rabies vaccine sales and a 19% increase in TBE vaccine sales.
Public Preparedness Success
Secured contracts for more than 3 million doses due to the mpox public health crisis, with revenues much higher than the base business.
Successful Tech Transfer
Tech transfer for rabies and TBE assets is on track, with rabies completed and TBE expected to be completed this year.
New Pipeline Assets
Announced two new pipeline assets for Lyme disease and Epstein-Barr virus, with clinical studies planned for 2026.
Chikungunya Vaccine Approvals
Chikungunya vaccine approved in the U.S. and EU, with plans to launch in major territories in the first half of the year.
---
BVNRY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BVNRY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 05, 2025 | $7.69 | $8.08 | +5.07% |
| Nov 15, 2024 | $9.68 | $7.96 | -17.77% |
| Aug 22, 2024 | $12.28 | $13.52 | +10.10% |
| May 08, 2024 | $7.83 | $7.82 | -0.13% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Bavarian Nordic A/S (BVNRY) report earnings?
Bavarian Nordic A/S (BVNRY) is schdueled to report earning on May 09, 2025, TBA Not Confirmed.
What is Bavarian Nordic A/S (BVNRY) earnings time?
Bavarian Nordic A/S (BVNRY) earnings time is at May 09, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BVNRY EPS forecast?
Currently, no data Available
---